237:
dose-ranging phase 2 study of Pexa-Vec in mainly sorafenib naĂŻve patients with advanced hepatocellular carcinoma demonstrated that the risk of death for patients who received Pexa-Vec at the high dose was markedly reduced (by nearly 60 percent; hazard ratio = 0.41) when compared to patients randomized to a low dose control (one-tenth of the high dose). The median overall survival for high and low dose groups was 14.1 months versus 6.7 months, respectively (p = 0.020 for superiority of the high dose). Pexa-Vec was well tolerated, with patients experiencing transient
112:
Pexa-Vec (JX-594) is the most advanced product candidate from SillaJen's proprietary SOLVE™ (Selective
Oncolytic Vaccinia Engineering) platform. SOLVE is used to optimize virus targeting to specific cancer types, to select transgenes to include into the viral genome, and to optimize viral infection
1120:
Heo, Jeong; Breitbach, Caroline; Cho, Mong; Hwang, Tae-Ho; Kim, Chang Won; Jeon, Ung Bae; Woo, Hyun Young; Yoon, Ki Tae; Lee, Jun Woo; Burke, James; Hickman, Theresa; Longpre, Lara; Patt, Richard H.; Kirn, David H. (2013-05-20). "Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an
236:
gene to stimulate a systemic anti-tumor immune response. Researchers believe that Pexa-Vec may be a systemic treatment of hepatocellular carcinoma by inducing tumor necrosis and shrinkage of both injected and non-injected tumors after direct intratumoral delivery. Final data from a randomized
215:
versus sorafenib is being conducted on patients with advanced hepatocellular carcinoma who have not previously received any systemic therapy. The study is being done to determine and compare overall survival for patients in the two treatment arms. The study is
Sponsored by SillaJen, Inc.
517:
to stimulate immune responses. In nonclinical studies, the JX-970 backbone exerted a tumor debulking effect and at the same time demonstrated a selective preference for tumor tissues. The precursor of JX-970 is JX-963 which demonstrated efficacy in pre-clinical studies.
899:
Parker, Charles Thomas; Garrity, George M (2003-01-01). Parker, Charles Thomas; Garrity, George M (eds.). "Exemplar
Abstract for Mycobacterium yongonense Kim et al. 2013 and Mycobacterium intracellulare yongonense (Kim et al. 2013) Castejon et al. 2018".
739:
Breitbach, Caroline J.; Burke, James; Jonker, Derek; Stephenson, Joe; Haas, Andrew R.; Chow, Laura Q. M.; Nieva, Jorge; Hwang, Tae-Ho; Moon, Anne (2011-08-31). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans".
1189:"A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma"
231:
virus engineered to stimulate anti-tumor immunity and directly lyse tumor cells. Pexa-Vec has cancer selectivity through the deactivation of its thymidine kinase gene, and it has been engineered to express the
1370:
Downs-Canner, Stephanie; Guo, Zong Sheng; Ravindranathan, Roshni; Breitbach, Caroline J; O'Malley, Mark E; Jones, Heather L; Moon, Anne; McCart, Judith Andrea; Shuai, Yongli (August 2016).
1313:
Zeh, Herbert J.; Downs-Canner, Stephanie; McCart, J. Andrea; Guo, Zong Sheng; Rao, Uma N. M.; Ramalingam, Lekshmi; Thorne, Stephen H.; Jones, Heather L.; Kalinski, Pawel (January 2015).
1008:
Zeh, Herbert J; Downs-Canner, Stephanie; McCart, J Andrea; Guo, Zong Sheng; Rao, Uma N M; Ramalingam, Lekshmi; Thorne, Stephen H; Jones, Heather L; Kalinski, Pawel (January 2015).
501:
via intratumoral & intravenous injections in a Phase 1, dose escalation clinical trial. This Phase 1 study showed delivery to and replication within tumors both IT and IV.
850:
Breitbach, Caroline J.; Arulanandam, Rozanne; De Silva, Naomi; Thorne, Steve H.; Patt, Richard; Daneshmand, Manijeh; Moon, Anne; Ilkow, Carolina; Burke, James (2013-02-15).
933:
514:
233:
199:
143:
430:
Participants will be randomly assigned to one of two treatment arms, having an equal chance of receiving either Pexa-Vec followed by sorafenib, or sorafenib alone.
1169:"A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) - Full Text View - ClinicalTrials.gov"
581:
1149:"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone - Full Text View - ClinicalTrials.gov"
799:
Kirn, David H.; Thorne, Steve H. (January 2009). "Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer".
1433:
582:
Transgene
Presents Data on Improved Cytotoxic Activity of Oncolytic Viruses Expressing Intrabodies in Resistant Tumor Cell Lines. October 2016
32:
149:
Blood flow to tumors can be blocked following intratumoral replication and spreadJX-900 (VVDD): VVDD Platform: Next-gen enhanced
64:
gene which limits viral replication to cells with high levels of thymidine kinase, typically seen in cancer cells with a mutated
571:
Phase 1 Study of
Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients
455:
Participants will visit the study center approximately 12 times over 18 weeks and receive sorafenib as per standard of care.
1121:
oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma".
1315:"First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity"
1010:"First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity"
94:
1213:"Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors"
534:
1148:
39:
1096:
660:
Breitbach at al. (2011). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans".
1212:
1188:
314:
1097:"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone"
445:
Following Pexa-Vec injection series completion, patients will receive sorafenib starting at week 6 of the study
98:
646:
158:
150:
1168:
913:
1438:
1274:
749:
669:
242:
1236:
980:
952:
832:
781:
714:
693:
251:
225:
124:
1372:"Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers"
78:
gene insertion under control of the p7.5 promoter. The virus kills the infected/cancer cells by
570:
473:
pipeline are engineered through the
Selective Oncolytic Vaccinia Engineering (SOLVE) platform.
1409:
1391:
1352:
1334:
1292:
1047:
1029:
881:
873:
824:
816:
773:
765:
685:
606:
498:
494:
1399:
1383:
1342:
1326:
1282:
1130:
1037:
1021:
901:
863:
808:
757:
677:
594:
552:
486:
173:
139:
61:
553:
Jennerex
Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
489:
and vaccinia growth factor. JX-929 has been administered as a monotherapy to patients with
926:
116:
104:
In clinical trials doses have been administered by intratumoral or intravenous injection.
20:
1278:
753:
673:
513:
and utilizes the same tumor selectivity mechanisms as JX-929. In addition, it expresses
42:, tested in clinical trials on melanoma patients, and licensed and further developed by
1404:
1371:
1347:
1314:
1042:
1009:
442:
All Pexa-Vec treatments (3) will be given by intratumoral injections into liver tumors.
247:
1134:
1427:
624:
490:
188:
65:
836:
785:
697:
24:
868:
851:
1072:
90:
439:
Participants will visit the study center approximately 14 times over 18 weeks.
411:
73:
1395:
1338:
1296:
1033:
877:
820:
769:
391:
386:
291:
238:
212:
1413:
1356:
1051:
885:
828:
777:
689:
1263:"Comment onKhazanov et al.[2002] andKhazanov et al.[2006]"
852:"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans"
647:"Novel Cancer-Targeting Virus Therapy Shows Efficacy in Early-Stage Trial"
610:
1287:
1262:
510:
485:
virus. JX-929's tumor selectivity has been optimized through deletion of
482:
470:
337:
228:
192:
184:
166:
53:
50:
43:
28:
1387:
1330:
1025:
761:
681:
905:
83:
57:
812:
142:
and “arming” for expression of therapeutic transgene products (e.g.
364:
360:
211:
A phase 3 randomized, open-label, clinical trial of Pexa-Vec plus
132:
120:
79:
169:
vaccine (Western
Reserve strain) with enhanced oncolytic potency
135:
of the infected cancer cell and spread to adjacent cancer cells
131:
Tumor selective intratumoral replication of the virus leads to
256:
Clinical trials investigating Pexa-Vec (as of June 2018)
177:
69:
183:
JX-929 (vvDD expressing CD for 5-FU pro-drug) experience in
113:
and/or replication selectively through targeted mutations.
49:
JX-594 is a modified
Copenhagen strain (or Wyeth strain)
86:
which may help initiate an anti-tumour immune response.
241:-like symptoms that generally resolved within 24 hours.
509:
JX-970 is also derived from a
Western Reserve strain
119:
could have 3-prolonged attack on cancer: direct cell
38:) and was constructed in Dr. Edmund Lattime's lab at
515:granulocyte-macrophage colony-stimulating factor
234:granulocyte-macrophage colony-stimulating factor
200:granulocyte-macrophage colony-stimulating factor
157:JX-900 (VVDD): VVDD Platform: Next-gen enhanced
975:
973:
1267:Journal of Geophysical Research: Space Physics
1003:
1001:
481:JX-929 is derived from Western Reserve strain
1261:Thorne, R. M.; Horne, R. B. (December 2007).
8:
1237:"JX-900 Series > Pipeline > Sillajen"
981:"JX-900 Series > Pipeline > Sillajen"
566:
564:
562:
560:
932:CS1 maint: DOI inactive as of April 2024 (
709:
707:
224:The experimental therapy, Pexa-Vec, is an
1403:
1346:
1286:
1041:
867:
595:"ras oncogenes in human cancer: a review"
172:Attenuation via “Double-Deletion” :
548:
546:
254:
220:Mechanism of Action of Pexa-Vec (Jx-594)
627:. National Cancer Institute. 2011-02-02
527:
947:
945:
943:
922:
911:
146:) enhance immune response to the tumor
1308:
1306:
1067:
1065:
1063:
1061:
953:"SOLVE > Technology > Sillajen"
715:"SOLVE > Technology > Sillajen"
434:Arm A: Pexa-Vec followed by sorafenib
7:
246:As of June 2018, these are the
202:) next generation of the VVDD series
23:is designed to target and destroy
14:
1135:10.1200/jco.2013.31.15_suppl.4122
165:JX-900 is a series of modified
1434:Experimental cancer treatments
1073:"General Information | PHOCUS"
97:and EUMA for the treatment of
72:gene. The virus also has the
56:engineered by addition of the
1:
869:10.1158/0008-5472.CAN-12-2687
593:Bos, JL (September 1, 1989).
127:activation, and antivascular
123:with replication and spread,
1123:Journal of Clinical Oncology
537:25 March 2012, Radio Canada
138:Induction of tumor-specific
95:Food and Drug Administration
469:Novel oncolytic viruses in
315:metronomic cyclophosphamide
40:Thomas Jefferson University
1455:
36:pexastimogene devacirepvec
535:Un virus contre le cancer
281:Hepatocellular carcinoma
275:
272:
269:
266:
263:
260:
60:gene and deletion of the
350:Colorectal Cancer 2L/3L
327:Renal Cell Carcinoma 2L
198:JX-970 (vvDD expressing
99:hepatocellular carcinoma
250:investigating Pexa-Vec.
159:oncolytic immunotherapy
151:oncolytic immunotherapy
140:cytotoxic T-lymphocytes
27:. It is also known as
921:Cite journal requires
908:(inactive 2024-04-17).
801:Nature Reviews. Cancer
178:vaccinia growth factor
625:"NCI Drug Dictionary"
1288:10.1029/2007ja012268
93:designation from US
1388:10.1038/mt.2016.101
1331:10.1038/mt.2014.194
1279:2007JGRA..11212214T
1026:10.1038/mt.2014.194
762:10.1038/nature10358
754:2011Natur.477...99B
682:10.1038/nature10358
674:2011Natur.477...99B
460:Pipeline candidates
257:
82:and also expresses
1217:ClinicalTrials.gov
1193:ClinicalTrials.gov
1129:(15_suppl): 4122.
1101:ClinicalTrials.gov
465:JX-Next Generation
255:
1376:Molecular Therapy
1319:Molecular Therapy
1014:Molecular Therapy
649:. 31 August 2011.
499:pancreatic cancer
423:
422:
180:gene inactivation
117:Oncolytic viruses
1446:
1418:
1417:
1407:
1382:(8): 1492–1501.
1367:
1361:
1360:
1350:
1310:
1301:
1300:
1290:
1258:
1252:
1251:
1249:
1248:
1241:www.sillajen.com
1233:
1227:
1226:
1224:
1223:
1209:
1203:
1202:
1200:
1199:
1185:
1179:
1178:
1176:
1175:
1165:
1159:
1158:
1156:
1155:
1145:
1139:
1138:
1117:
1111:
1110:
1108:
1107:
1093:
1087:
1086:
1084:
1083:
1069:
1056:
1055:
1045:
1005:
996:
995:
993:
992:
985:www.sillajen.com
977:
968:
967:
965:
964:
957:www.sillajen.com
949:
938:
937:
930:
924:
919:
917:
909:
906:10.1601/ex.23701
896:
890:
889:
871:
862:(4): 1265–1275.
847:
841:
840:
796:
790:
789:
748:(7362): 99–102.
736:
730:
729:
727:
726:
719:www.sillajen.com
711:
702:
701:
668:(7362): 99–102.
657:
651:
650:
643:
637:
636:
634:
632:
621:
615:
614:
590:
584:
579:
573:
568:
555:
550:
541:
540:
532:
487:thymidine kinase
450:Arm B: sorafenib
258:
174:thymidine kinase
101:(liver cancer).
62:thymidine kinase
1454:
1453:
1449:
1448:
1447:
1445:
1444:
1443:
1424:
1423:
1422:
1421:
1369:
1368:
1364:
1312:
1311:
1304:
1260:
1259:
1255:
1246:
1244:
1235:
1234:
1230:
1221:
1219:
1211:
1210:
1206:
1197:
1195:
1187:
1186:
1182:
1173:
1171:
1167:
1166:
1162:
1153:
1151:
1147:
1146:
1142:
1119:
1118:
1114:
1105:
1103:
1095:
1094:
1090:
1081:
1079:
1071:
1070:
1059:
1007:
1006:
999:
990:
988:
979:
978:
971:
962:
960:
951:
950:
941:
931:
920:
910:
898:
897:
893:
856:Cancer Research
849:
848:
844:
813:10.1038/nrc2545
798:
797:
793:
738:
737:
733:
724:
722:
713:
712:
705:
659:
658:
654:
645:
644:
640:
630:
628:
623:
622:
618:
599:Cancer Research
592:
591:
587:
580:
576:
569:
558:
551:
544:
538:
533:
529:
524:
507:
479:
467:
462:
452:
436:
428:
248:clinical trials
222:
209:
207:Clinical trials
110:
21:oncolytic virus
12:
11:
5:
1452:
1450:
1442:
1441:
1436:
1426:
1425:
1420:
1419:
1362:
1325:(1): 202–214.
1302:
1253:
1228:
1204:
1180:
1160:
1140:
1112:
1088:
1057:
1020:(1): 202–214.
997:
969:
939:
923:|journal=
891:
842:
791:
731:
703:
652:
638:
616:
605:(17): 4682–9.
585:
574:
556:
542:
526:
525:
523:
520:
511:vaccinia virus
506:
503:
478:
475:
466:
463:
461:
458:
457:
456:
451:
448:
447:
446:
443:
440:
435:
432:
427:
424:
421:
420:
417:
414:
410:Combined with
408:
405:
402:
398:
397:
394:
389:
385:Combined with
383:
380:
377:
373:
372:
370:
367:
359:Combined with
357:
354:
351:
347:
346:
343:
340:
336:Combined with
334:
331:
328:
324:
323:
320:
317:
313:Combined with
311:
308:
305:
301:
300:
297:
294:
290:Combined with
288:
285:
282:
278:
277:
274:
271:
268:
265:
262:
221:
218:
208:
205:
204:
203:
196:
181:
170:
155:
154:
147:
136:
109:
106:
13:
10:
9:
6:
4:
3:
2:
1451:
1440:
1437:
1435:
1432:
1431:
1429:
1415:
1411:
1406:
1401:
1397:
1393:
1389:
1385:
1381:
1377:
1373:
1366:
1363:
1358:
1354:
1349:
1344:
1340:
1336:
1332:
1328:
1324:
1320:
1316:
1309:
1307:
1303:
1298:
1294:
1289:
1284:
1280:
1276:
1272:
1268:
1264:
1257:
1254:
1242:
1238:
1232:
1229:
1218:
1214:
1208:
1205:
1194:
1190:
1184:
1181:
1170:
1164:
1161:
1150:
1144:
1141:
1136:
1132:
1128:
1124:
1116:
1113:
1102:
1098:
1092:
1089:
1078:
1074:
1068:
1066:
1064:
1062:
1058:
1053:
1049:
1044:
1039:
1035:
1031:
1027:
1023:
1019:
1015:
1011:
1004:
1002:
998:
986:
982:
976:
974:
970:
958:
954:
948:
946:
944:
940:
935:
928:
915:
907:
903:
895:
892:
887:
883:
879:
875:
870:
865:
861:
857:
853:
846:
843:
838:
834:
830:
826:
822:
818:
814:
810:
806:
802:
795:
792:
787:
783:
779:
775:
771:
767:
763:
759:
755:
751:
747:
743:
735:
732:
720:
716:
710:
708:
704:
699:
695:
691:
687:
683:
679:
675:
671:
667:
663:
656:
653:
648:
642:
639:
626:
620:
617:
612:
608:
604:
600:
596:
589:
586:
583:
578:
575:
572:
567:
565:
563:
561:
557:
554:
549:
547:
543:
536:
531:
528:
521:
519:
516:
512:
504:
502:
500:
496:
492:
488:
484:
476:
474:
472:
464:
459:
454:
453:
449:
444:
441:
438:
437:
433:
431:
425:
418:
416:Investigator
415:
413:
409:
406:
403:
401:Solid Tumors
400:
399:
395:
393:
390:
388:
384:
381:
378:
376:Liver Cancer
375:
374:
371:
369:Investigator
368:
366:
362:
358:
355:
352:
349:
348:
344:
341:
339:
335:
332:
329:
326:
325:
321:
319:Investigator
318:
316:
312:
309:
306:
304:Solid Tumors
303:
302:
298:
295:
293:
289:
286:
283:
280:
279:
259:
253:
252:
249:
244:
243:
240:
235:
230:
227:
219:
217:
214:
206:
201:
197:
194:
190:
186:
182:
179:
175:
171:
168:
164:
163:
162:
160:
152:
148:
145:
141:
137:
134:
130:
129:
128:
126:
122:
118:
114:
107:
105:
102:
100:
96:
92:
87:
85:
81:
77:
76:
71:
67:
63:
59:
55:
52:
47:
45:
41:
37:
34:
30:
26:
22:
18:
1379:
1375:
1365:
1322:
1318:
1273:(A12): n/a.
1270:
1266:
1256:
1245:. Retrieved
1240:
1231:
1220:. Retrieved
1216:
1207:
1196:. Retrieved
1192:
1183:
1172:. Retrieved
1163:
1152:. Retrieved
1143:
1126:
1122:
1115:
1104:. Retrieved
1100:
1091:
1080:. Retrieved
1076:
1017:
1013:
989:. Retrieved
984:
961:. Retrieved
956:
914:cite journal
894:
859:
855:
845:
807:(1): 64–71.
804:
800:
794:
745:
741:
734:
723:. Retrieved
718:
665:
661:
655:
641:
629:. Retrieved
619:
602:
598:
588:
577:
530:
508:
480:
468:
429:
426:Study Design
419:NCT02977156
396:NCT03071094
345:NCT03294083
322:NCT02630368
299:NCT02562755
245:
223:
210:
185:solid tumors
156:
115:
111:
103:
88:
74:
48:
35:
25:cancer cells
16:
15:
1439:Virotherapy
1243:(in Korean)
987:(in Korean)
959:(in Korean)
721:(in Korean)
539:(in French)
407:Recruiting
382:Recruiting
356:Recruiting
333:Recruiting
310:Recruiting
287:Recruiting
261:Indication
91:orphan drug
1428:Categories
1247:2018-06-16
1222:2018-06-16
1198:2018-06-16
1174:2018-06-16
1154:2018-06-16
1106:2018-06-27
1082:2018-06-27
991:2018-06-17
963:2018-06-16
725:2018-06-17
522:References
495:colorectal
412:Ipilimumab
226:attenuated
108:Technology
1396:1525-0016
1339:1525-0024
1297:0148-0227
1034:1525-0016
878:1538-7445
821:1474-1768
770:1476-4687
392:Transgene
387:Nivolumab
342:SillaJen
296:SillaJen
292:sorafenib
213:sorafenib
1414:27203445
1357:25292189
1077:SillaJen
1052:25292189
886:23393196
837:20344137
829:19104515
778:21886163
690:21886163
631:25 March
483:vaccinia
471:SillaJen
338:REGN2810
273:Sponsor
229:vaccinia
193:melanoma
167:vaccinia
54:poxvirus
51:vaccinia
44:SillaJen
29:Pexa-Vec
1405:5023393
1348:4426804
1275:Bibcode
1043:4426804
786:4365604
750:Bibcode
698:4365604
670:Bibcode
611:2547513
267:Status
89:It has
1412:
1402:
1394:
1355:
1345:
1337:
1295:
1050:
1040:
1032:
884:
876:
835:
827:
819:
784:
776:
768:
742:Nature
696:
688:
662:Nature
609:
505:JX-970
497:, and
491:breast
477:JX-929
270:Notes
264:Phase
144:GM-CSF
125:immune
84:GM-CSF
58:GM-CSF
19:is an
17:JX-594
833:S2CID
782:S2CID
694:S2CID
365:CTLA4
361:PD-L1
133:lysis
121:lysis
80:lysis
1410:PMID
1392:ISSN
1353:PMID
1335:ISSN
1293:ISSN
1048:PMID
1030:ISSN
934:link
927:help
882:PMID
874:ISSN
825:PMID
817:ISSN
774:PMID
766:ISSN
686:PMID
633:2013
607:PMID
363:and
284:III
276:Ref
191:and
176:and
75:LacZ
1400:PMC
1384:doi
1343:PMC
1327:doi
1283:doi
1271:112
1131:doi
1038:PMC
1022:doi
902:doi
864:doi
809:doi
758:doi
746:477
678:doi
666:477
307:II
239:flu
189:CRC
70:p53
68:or
66:RAS
33:INN
1430::
1408:.
1398:.
1390:.
1380:24
1378:.
1374:.
1351:.
1341:.
1333:.
1323:23
1321:.
1317:.
1305:^
1291:.
1281:.
1269:.
1265:.
1239:.
1215:.
1191:.
1127:31
1125:.
1099:.
1075:.
1060:^
1046:.
1036:.
1028:.
1018:23
1016:.
1012:.
1000:^
983:.
972:^
955:.
942:^
918::
916:}}
912:{{
880:.
872:.
860:73
858:.
854:.
831:.
823:.
815:.
803:.
780:.
772:.
764:.
756:.
744:.
717:.
706:^
692:.
684:.
676:.
664:.
603:49
601:.
597:.
559:^
545:^
493:,
404:I
379:I
353:I
330:I
161:.
46:.
31:,
1416:.
1386::
1359:.
1329::
1299:.
1285::
1277::
1250:.
1225:.
1201:.
1177:.
1157:.
1137:.
1133::
1109:.
1085:.
1054:.
1024::
994:.
966:.
936:)
929:)
925:(
904::
888:.
866::
839:.
811::
805:9
788:.
760::
752::
728:.
700:.
680::
672::
635:.
613:.
195:)
187:(
153:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.